Serina Therapeutics Inc. (SER)
NYSE: SERHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 3:59 PM ET · Delayed 15 min
SER stock chart
Technical analysisKey statistics
All statistics- Market cap
- $29.76M
- EPS (TTM)
- -$1.63
- Dividend yield
- None
- 52-week range
- 1.06 – 4.26
- Day range
- 1.06 – 1.26
- Volume / Avg
- 62.15K / 68.98K
- Beta
- —
- Shares outstanding
- 26.57M
- Next earnings
- Nov 26, 2026
52-week range
SER stock today
On Nov 20, SER ended the session at $1.12, shedding $0.08 (6.67%), versus the S&P 500's 3.70% decline. At this level, SER sits near the bottom of its 52-week range of $1.06 to $4.26: 73.7% below the high, set on Nov 28, 2025 and 5.7% above the low. SER is down 41.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 71.9%.
Serina Therapeutics has posted a net loss over the last twelve months (EPS of -$1.63), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 26.
Summary generated from market data by MetaCap's automated system. Methodology
About Serina Therapeutics
Company profileSerina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Steven A. Ledger
- Headquarters
- Huntsville, AL
- Employees
- 16
- IPO year
- 2018
- Website
- serinatherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Serina Therapeutics generated $130,000 in revenue, up 132.1% from fiscal 2024. Serina Therapeutics reported a net loss of $19.2 million, compared with a loss of $11.1 million a year earlier. Operating margin was -18478.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $130.00K | $56.00K | $3.15M | $34.00K | $144.00K |
| Growth | +132.14% | -98.22% | +9173.53% | -76.39% | -60.11% |
| Net income | $-19.18M | $-11.14M | $5.27M | $-10.46M | $-8.68M |
| EPS (diluted) | $-1.91 | $-1.51 | $0.73 | $-9.70 | $-0.23 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$9.50+748.21%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 26, 2026
- Last reported (Sep/2026)
- Nov 19, 2026
- EPS actual vs est.
- $-0.45 vs —
SER news
All SER newsSerina Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NXTCNextCure Inc. | 6.45 | -4.87% | $29.53M | vs SER |
| NNVCNanoViricides Inc. | 1.14 | -2.56% | $29.13M | vs SER |
| RNTXRein Therapeutics Inc. | 0.3369 | -8.38% | $29.06M | vs SER |
| ATHEAlterity Therapeutics Limited ADR | 1.52 | -8.16% | $29.02M | vs SER |
| AYTUAytu BioPharma Inc. | 2.66 | 0.00% | $28.91M | vs SER |
| PMNProMIS Neurosciences Inc. | 3.16 | -1.56% | $28.43M | vs SER |
| FLNAFilana Therapeutics Inc. | 0.6413 | +14.52% | $32.26M | vs SER |
| GRDXGridAI Technologies Corp. | 3.16 | -8.41% | $32.44M | vs SER |
Indexes, lists and sector
Serina Therapeutics stock FAQ
What is Serina Therapeutics's stock price today?
SER last traded at $1.12 as of Nov 20, 3:59 PM EST, down 6.67% on the day. Prices are delayed at least 15 minutes.
Does Serina Therapeutics pay a dividend?
No. Serina Therapeutics does not currently pay a regular cash dividend.
When is Serina Therapeutics's next earnings date?
Serina Therapeutics is expected to report earnings on Thursday, November 26, 2026.
Who is Serina Therapeutics's CEO?
Mr. Steven A. Ledger is the chief executive officer of Serina Therapeutics Inc., which has about 16 employees.
Has SER ever split its stock?
Yes. The most recent SER stock split was a 28-for-1000 split on Mar 15, 2024.
What is the SER 52-week high?
The 52-week high for SER is $4.26 and the 52-week low is $1.06. The stock is currently 73.7% below its high.